NASD · Healthcare · Medical Devices · USA
Elutia Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.
Elutia develops drug-eluting biomatrix products for surgical reconstruction and related medical applications. The company creates biologic matrix solutions combined with local drug delivery to address surgical complications including infection and inflammation. Elutia markets proprietary products like SimpliDerm for soft tissue reconstruction and cardiovascular repair products, while advancing next-generation biomatrix technologies.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Elutia Inc stock.
Overvalued: intrinsic value $0.48 per share, market price $0.85, margin of safety -78.9% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $0.48; the price of $0.85 is 79% above that value.
All 140 Medical Devices stocks
36 more in this industry show a wider margin of safety.
ELUT is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.48; the price of $0.85 is 79% above that value.
$0.48 per share (as of the 2026-11-17 close), against a market price of $0.85. That is a margin of safety of -78.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.